The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery

• Published in: European respiratory review 2024-01, Vol.33 (171), p.230127
• Main Authors: Kolanko, Emanuel, Cargnoni, Anna, Papait, Andrea, Silini, Antonietta Rosa, Czekaj, Piotr, Parolini, Ornella
• Format: Article
• Language: English
• Subjects: Disease Progression; Drug Discovery; Endothelial Cells - pathology; Humans; Idiopathic Pulmonary Fibrosis - pathology; Lung Diseases, Interstitial; Reviews
• ISSN: 0905-9180; 1600-0617
• DOI: 10.1183/16000617.0127-2023

Lung fibrosis is a complex process, with unknown underlying mechanisms, involving various triggers, diseases and stimuli. Different cell types (epithelial cells, endothelial cells, fibroblasts and macrophages) interact dynamically through multiple signalling pathways, including biochemical/molecular and mechanical signals, such as stiffness, affecting cell function and differentiation. Idiopathic pulmonary fibrosis (IPF) is the most common fibrosing interstitial lung disease (fILD), characterised by a notably high mortality. Unfortunately, effective treatments for advanced fILD, and especially IPF and non-IPF progressive fibrosing phenotype ILD, are still lacking. The development of pharmacological therapies faces challenges due to limited knowledge of fibrosis pathogenesis and the absence of pre-clinical models accurately representing the complex features of the disease. To address these challenges, new model systems have been developed to enhance the translatability of preclinical drug testing and bridge the gap to human clinical trials. The use of two- and three-dimensional cultures derived from healthy or diseased individuals allows for a better understanding of the underlying mechanisms responsible for lung fibrosis. Additionally, microfluidics systems, which replicate the respiratory system's physiology , offer promising opportunities for the development of effective therapies, especially for IPF.